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CASO CLÍNICO/CASE REPORT
Síndrome de Gilles de La Tourette: Relato de Caso com Diagnóstico Tardio
Gilles de La Tourette Syndrome: Late Diagnosis Case Report
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Resumo
A síndrome de Gilles de La Tourette é uma doença neuropsiquiátrica que afeta cerca de 1% da população. Tem início 
frequente na infância ou adolescência precoce. Os tiques, manifestação central, tendem a diminuir em frequência e 
gravidade durante a adolescência, existindo uma pequena percentagem de casos que evolui para doença grave. 
A propósito de um caso clínico de uma doente com 28 anos, com diagnóstico tardio aos 18 anos, doença grave e sem 
resposta ao tratamento, apresenta ‑se uma revisão de fatores de prognóstico, manutenção e indicações para alternativa 
cirúrgica na doença resistente.
A fisiopatologia não está definida, não existindo tratamento eficaz comprovada para estes indivíduos. Existem 
alternativas quando o tratamento com psicofármacos não é eficaz e considera -se proposta cirúrgica neste caso. 
Destaca ‑se a importância de uma boa articulação entre a Psiquiatria da Infância e Adolescência, a Psiquiatria e os 
Cuidados Primários. Conclui -se que serão necessários mais estudos para definir e individualizar o tratamento em casos 
de doença resistente.
Abstract
Gilles de la Tourette syndrome is a neuropsychiatric disease that affects about 1% of the population with frequent on‑
set during childhood or early adolescence. Tics, the central manifestation, tend to decrease in frequency and severity 
throughout adolescence, even though a small percentage of cases progress to severe illness.
We present a clinical case description of a 28 ‑year ‑old patient late diagnosed at 18 years old, with severe disease and no 
response to treatment as well as a prognostic and maintenance factor exploration and surgical indication in pharmacolo‑
gical resistant cases. 
The pathophysiology is not well established and there is no approved treatment for all patients. There are alternatives 
when psychotropic drugs are not effective and a surgical intervention is considered in this case. 
We highlight the importance of a good co ‑work and communication between Child and Adolescent Psychiatry, Psychiatry 
and Primary Care and early diagnosis. Further studies and evidence will be necessary to define and individualize resistant 
cases treatment.
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INTRODUCTION
Gilles de La Tourette syndrome (GTS) is a polygenic neu‑
ropsychiatric disorder characterized by persistent motor 
and vocal tics (more than one), during at least 12 mon‑
ths.1 Motor and verbal tics may not have a simultaneous 
presentation; symptom onset occurs before 18 years and 
tics cannot be explained by other medical conditions.1,2 
GTS estimated prevalence is around 1%, predominantly 
affecting male gender.3,4 Tics can persist throughout 
adulthood with a severe and debilitating presentation in a 
76 Sofia Pires
minority of cases.1,5 Tics also have a sensory component 
 ‑ premonitory urge  ‑ which precedes the tic.6 
GTS pathophysiology is not well established. There is 
some evidence of abnormalities in brain pathways, particu‑
larly in the cortico ‑basal ganglia ‑thalamocortical circuit.7 
It has a complex and multifactorial etiology. Currently, 
there is no specific diagnostic exam or laboratory analysis 
that defines GTS.8
Tic exacerbation related to stress is well established 
and worsening of symptoms correlates with adverse life 
events.9 The transition period between adolescence and 
adulthood presents itself as a critical phase. Quality of 
life in these individuals exposed to potential social stigma 
tends to decrease.10 
Comorbid or co ‑occurring conditions are common (in 90% 
of cases  - attention deficit and hyperactivity disorder in 
21% ‑90%, obsessive compulsive disorder (OCD) in 20%‑
‑60%, depression in 18% ‑30% and anxiety disorder in 
18%).11
We pretend to present a GTS clinical case with severe and 
debilitating symptoms, comorbid OCD, resistance to the‑
rapy and explore maintenance factors as well as alternative 
surgery treatment indications. 
CASE REPORT
The case study refers to a 28 ‑year ‑old female patient, sin‑
gle, working as a communication advisor.
Around the age of 18 she presents with simple motor tics 
(eye blinking), simple vocal tics (guttural sounds) and 
echolalia associated with obsessive compulsive symptoms 
of contamination and religious rituals  ‑ blessing herself 
repeatedly. These were associated with intrusive thoughts 
of tragic content.
Meanwhile, she develops a conflicting relationship with 
her teacher and faces a complex process of decisions and 
changes: the choice of future education and work, admis‑
sion to college and adolescence. Her parents decide to 
split up and she is forced to live with her alcoholic father 
with whom she has an unstable relationship. All these life‑
‑events ended up conditioning the worsening of tics asso‑
ciated with depressive symptoms that motivated a medical 
appointment. It was then prescribed an antidepressant by 
the attending physician. In an early phase, tics were not a 
source of concern to her family. 
Around the age of 20 she develops coprolalia and self‑
‑aggressive motor tics, sometimes causing bruises, which 
motivates a psychiatry appointment. In association, she 
presents increasing obsessive, intrusive, egodystonic 
thoughts, with a worsening anxiety component, initial 
insomnia and cognitive complaints due to lack of concen‑
tration at work. She was victim of mobbing and suffered 
successive dismissals. When in a professional environ‑
ment she managed to control some tics and rituals with a 
lot of effort and self ‑control, getting exhausted and giving 
up work. In peaceful and familiar environments, the symp‑
toms tended to be worse and constant, as rebound from 
controlling attempts or more stress/conflicts at home as her 
father did not understand the disease. 
She starts regular monitoring with a Psychiatrist and under‑
goes evaluation in a Neurology appointment with further 
investigation, without alterations. She is diagnosed with 
GTS and OCD. After a succession of adverse life ‑events 
the patient’ symptoms get worse and she starts treatment 
due to the negative impact and daily dysfunctionality. In 
addition to psychotherapy she starts pharmacotherapy with 
antipsychotics and antidepressants for comorbid OCD. She 
undergoes several switches (typical antipsychotics – halo‑
peridol – and atypical antipsychotics – paliperidone, que‑
tiapine), tricyclic antidepressants (clomipramine), selective 
serotonin -reuptake inhibitors (fluvoxamine, escitalopram) 
benzodiazepines (mexazolam, alprazolam, clonazepam, 
diazepam) after titration to therapeutic doses and adequate 
treatment exposure due to side effects, lack of disease con‑
trol or no results at all, showing resistance to treatment. 
She maintains tics, coprolalia and obsessive symptoms 
with negative repercussions on social, professional, family 
and individual functioning. Her insight, clinically stable 
comorbidities and the resistance to other treatments make 
this patient a suitable candidate for Deep Brain Stimulation.
DISCUSSION
There is no treatment with proven efficacy for all GTS in‑
dividuals as in consequence of phenotypic variability and 
impact on functionality.12 Treatment must be individuali‑
zed and centered on psychoeducation in a social context.13 
Many patients do not require treatment when tics do not 
interfere with their normal daily functioning.12
The therapeutic options available for tic control are prima‑
rily cognitive ‑behavioral therapy, followed by the admi‑
nistration of psychotropic drugs and, in some cases, brain 
surgery.14 
Pharmacological treatment should be considered in pa‑
tients with tics that cause dysfunction and interfere with 
functional and cognitive performance.14 Presently, there is 
no medication that has proven efficacy for all individuals 
with TS or that changes clinical outcomes.12 Typical antip‑
sychotics are indicated for the treatment of tics, however, 
in low doses due to their side effects.13,14 Alternatively, 
atypical antipsychotics are recommended. There is not 
sufficient evidence to determine the relative effectiveness 
between different antipsychotics.13,14 Botulinum toxin, an‑
ticonvulsants, benzodiazepines and cannabinoid compou‑
nds are also described, however it is necessary to consider 
their side effects and limited evidence.13,14 There is a wide 
range of promising agents under investigation.13
There are no established criteria for treatment ‑refractory 
GTS. Phenotypic and genetic variability as well as dif‑
ferent comorbidities (that also contribute to deterioration 
in quality of life) make it difficult to reach a definition. 
Nevertheless, it was suggested that the failure of three dif‑
ferent drugs including both typical and atypical neurolep‑
tics in adequate dosages over an adequate period of time) 
and, if possible, at least 12 behavioral therapy sessions, 
implicated treatment resistance. Also, lack of response to 
haloperidol (the only drug licensed for GTS treatment in 
most of European countries).15
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There are no defined predictors of clinical course in GTS. 
It has a very heterogeneous presentation, a complex range 
of possible symptom combination and comorbidities and 
prognosis is difficult to define individually.16
Psychosocial problems might predict a more severe clini‑
cal outcome.16 In the majority of cases there is a comorbid 
condition that adds an extra clinical burden. OCD symp‑
tom severity directly influences tic symptom severity and 
depression directly influences quality of life in these indi‑
viduals. 11
Referring to the presented clinical case, the late diagnosis 
(at 18 years of age, when there was evidence of previous 
symptomatology in adolescence) stands out  ‑ perhaps due 
to the lack of information and awareness in the family, 
lack of articulation between medical specialties or mental 
health associated stigma  ‑ and the evolution to severe ill‑
ness (unlike most cases). Maintenance factors can be iden‑
tified, such as: lack of family support, concomitant OCD 
and depression, psychopharmacological intolerance or no 
response, professional and social life negative impact and 
family instability. 
Besides late diagnosis, she did not tolerate haloperidol 
beside 1mg/day and the combination of antipsychotics and 
antidepressants or benzodiazepines did not cause sympto‑
matic improvement. Despite not having behavioral therapy 
sessions, it can be considered a treatment refractory case. 
Given symptom severity and impact on patient’s psycho‑
social functioning, other therapeutic options may be con‑
sidered. Deep brain stimulation is an option in treatment 
resistance. There is limited data and no consensus on the 
brain target to stimulate.8 Like in any surgical procedure, 
there are risks and complications. Movement Disorders 
Society and the American Academy of Neurology recom‑
mend diagnostic confirmation and decision in a multidisci‑
plinary team with pre and post ‑surgical follow ‑up and the 
stabilization of comorbid psychiatric conditions.12,17
In short, we highlight the importance of co ‑work and 
communication between medical specialties in order to 
raise awareness, aiming for an early diagnosis and treat‑
ment of GTS patients. Deep brain stimulation is an option 
in treatment resistance. Further studies and evidence will 
be necessary to define and individualize treatment options. 
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